Lista de obras - Nancy Haigwood - Dominio Público Uruguay

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

scientific article published on 01 September 2019

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens

artículo científico publicado en 2016

Animal models for perinatal transmission of HIV-1.

artículo científico publicado en 2006

Animal models in HIV-1 protection and therapy

artículo científico publicado en 2015

Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine

artículo científico publicado el 1 de mayo de 1992

Antibody Reactivity to Deletion Mutants of the HIV-1 SF2 Envelope

article

Blocking and tackling HIV

article

B‐Cell Abnormalities in AIDS: Stable and Clonally‐Restricted Antibody Response in HIV‐1 Infection ⬇️

artículo científico publicado el 1 de octubre de 1993

Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells

artículo científico publicado en 2012

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge

artículo científico publicado en 2017

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques

artículo científico publicado en 2006

Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis ⬇️

artículo científico publicado el 1 de octubre de 1992

DNA sequence organization of the beta-globin complex in the BALB/c mouse.

artículo científico publicado en 1980

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

artículo científico publicado en 2003

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

artículo científico publicado en 2002

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

artículo científico publicado en 2022

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

artículo científico publicado en 2017

Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides.

artículo científico publicado en 2005

Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120 ⬇️

artículo científico publicado el 1 de junio de 1992

E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells

artículo científico publicado en 2016

Early Postinfection Antiviral Treatment Reduces Viral Load and Prevents CD4+Cell Decline in HIV Type 2-Infected Macaques ⬇️

artículo científico publicado el 1 de noviembre de 1997

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

artículo científico publicado en 2016

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells ⬇️

artículo científico publicado el 25 de julio de 1991

Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques

artículo científico publicado en 2021

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1

artículo científico publicado en 2014

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

artículo científico publicado en 2014

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

artículo científico publicado en 2006

Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

artículo científico publicado en 2016

Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.

artículo científico publicado en 1994

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

artículo científico publicado en 2018

Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells ⬇️

artículo científico publicado el 1 de noviembre de 1991

Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies

artículo científico publicado en 2015

HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

artículo científico publicado en 2010

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans

artículo científico publicado en 2013

HIV-1 envelope gp120 alters astrocytes in human brain cultures.

artículo científico publicado en 1993

HIV: tied down by its own receptor.

artículo científico publicado en 2015

Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques

artículo científico publicado en 2017

High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection

artículo científico publicado en 2009

Human natural killer cells mediate adaptive immunity to viral antigens

scientific article published on 01 May 2019

IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine

artículo científico publicado en 2019

Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

artículo científico publicado en 2009

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

artículo científico publicado en 2004

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

artículo científico publicado en 2013

Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge ⬇️

artículo científico publicado el 15 de marzo de 1992

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

artículo científico publicado en 2016

Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity.

artículo científico publicado en 2005

Introduction

artículo científico publicado en 2010

Lessons in Nonhuman Primate Models for AIDS Vaccine Research: From Minefields to Milestones ⬇️

artículo científico publicado el 1 de junio de 2012

Locations of three repetitive sequence families found in BALB/c adult β-globin clones ⬇️

artículo científico publicado el 11 de marzo de 1981

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

artículo científico publicado en 2007

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially

artículo científico publicado en 2012

Multigene DNA prime-boost vaccines for SHIV89.6P

article

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

artículo científico publicado en 2003

Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA

artículo científico publicado en 2014

Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

artículo científico publicado en 2007

Neutralizing antibodies and control of HIV: moves and countermoves.

artículo científico

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

artículo científico publicado en 1999

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques

artículo científico publicado en 2013

New recombinant vaccines based on the use of prokaryotic antigen-display systems.

artículo científico publicado en 2004

Passive and active antibody studies in primates to inform HIV vaccines.

artículo científico publicado en 2018

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

article

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

artículo científico publicado en 2010

Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina.

artículo científico publicado en 2004

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques

artículo científico publicado en 2017

Protection from pathogenic SIV challenge using multigenic DNA vaccines

scientific article published on 01 March 1999

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

artículo científico publicado en 2005

Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.

artículo científico publicado en 2018

Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.

artículo científico publicado en 1994

Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.

artículo científico publicado en 1995

SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans

artículo científico publicado en 2013

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

artículo científico publicado en 2011

The recognition site of type II restriction enzyme BglI is interrupted

artículo científico publicado en 1980

The use of nonhuman primate models in HIV vaccine development

artículo científico publicado en 2008

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

artículo científico publicado en 2004

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

artículo científico publicado en 2003

Transmission of HIV-1 in the face of neutralizing antibodies

artículo científico publicado en 2007

U.S.-Japan Cooperative Medical Science Program. 10th International Conference on Emerging Infectious Diseases in the Pacific Rim

scientific article published on 26 June 2007

Use of broadly neutralizing antibodies for HIV-1 prevention

artículo científico publicado en 2017

Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity

artículo científico publicado en 2014

Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini

artículo científico publicado en 1989

Lista de obras de Nancy Haigwood

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens

Animal models for perinatal transmission of HIV-1.

Animal models in HIV-1 protection and therapy

Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine

Antibody Reactivity to Deletion Mutants of the HIV-1 SF2 Envelope

Blocking and tackling HIV

B‐Cell Abnormalities in AIDS: Stable and Clonally‐Restricted Antibody Response in HIV‐1 Infection ⬇️

Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques

Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis ⬇️

DNA sequence organization of the beta-globin complex in the BALB/c mouse.

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides.

Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120 ⬇️

E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells

Early Postinfection Antiviral Treatment Reduces Viral Load and Prevents CD4+Cell Decline in HIV Type 2-Infected Macaques ⬇️

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells ⬇️

Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells ⬇️

Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies

HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans

HIV-1 envelope gp120 alters astrocytes in human brain cultures.

HIV: tied down by its own receptor.

Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques

High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection

Human natural killer cells mediate adaptive immunity to viral antigens

IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine

Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge ⬇️

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity.

Introduction

Lessons in Nonhuman Primate Models for AIDS Vaccine Research: From Minefields to Milestones ⬇️

Locations of three repetitive sequence families found in BALB/c adult β-globin clones ⬇️

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially

Multigene DNA prime-boost vaccines for SHIV89.6P

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA

Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

Neutralizing antibodies and control of HIV: moves and countermoves.

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques

New recombinant vaccines based on the use of prokaryotic antigen-display systems.

Passive and active antibody studies in primates to inform HIV vaccines.

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina.

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques

Protection from pathogenic SIV challenge using multigenic DNA vaccines

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.

Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.

Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.

SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

The recognition site of type II restriction enzyme BglI is interrupted

The use of nonhuman primate models in HIV vaccine development

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

Transmission of HIV-1 in the face of neutralizing antibodies

U.S.-Japan Cooperative Medical Science Program. 10th International Conference on Emerging Infectious Diseases in the Pacific Rim

Use of broadly neutralizing antibodies for HIV-1 prevention

Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity